The effects of etidronate on brain calcifications in Fahr's disease or syndrome: rationale and design of the randomised, placebo-controlled, double-blind CALCIFADE trial.

导出 OA

翻译打印收藏纠错

第一作者： Birgitta Mg,Snijders

第一单位： Department of Geriatrics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. b.m.g.snijders@umcutrecht.nl.

作者： Birgitta Mg,Snijders ^[1] ; Gini,Mathijssen ^[2] ; Mike Jl,Peters ^[2] ; Marielle H,Emmelot-Vonk ^[3] ; Pim A,de Jong ^[2] ; Susan,Bakker ^[4] ; Heleen A,Crommelin ^[2] ; Ynte M,Ruigrok ^[5] ; Eva H,Brilstra ^[6] ; Vera Pm,Schepers ^[7] ; Wilko,Spiering ^[8] ; Evelien,van Valen ^[9] ; Huiberdina L,Koek ^[3]

作者单位： Department of Geriatrics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. b.m.g.snijders@umcutrecht.nl. ^[1] Department of Geriatrics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[2] Department of Internal Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[3] Department of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[4] Department of Physiotherapy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[5] Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[6] Department of Neurology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[7] Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[8] Department of Rehabilitation, Physical Therapy, Science & Sports, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[9]

关键词 Brain calcifications Cognitive functioning Etidronate Fahr’s disease Fahr’s syndrome Primary Familial Brain Calcification Randomised-controlled trial